Crestline Management LP purchased a new stake in shares of Allergan plc (NYSE:AGN) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 28,930 shares of the company’s stock, valued at approximately $4,732,000. Allergan accounts for about 0.5% of Crestline Management LP’s holdings, making the stock its 15th largest position.
Other institutional investors have also recently made changes to their positions in the company. Windward Capital Management Co. CA grew its stake in Allergan by 9.4% in the fourth quarter. Windward Capital Management Co. CA now owns 3,475 shares of the company’s stock valued at $568,000 after purchasing an additional 298 shares during the last quarter. Graybill Bartz & Assoc Ltd. grew its stake in Allergan by 1.7% in the fourth quarter. Graybill Bartz & Assoc Ltd. now owns 18,456 shares of the company’s stock valued at $3,019,000 after purchasing an additional 305 shares during the last quarter. ETRADE Capital Management LLC grew its stake in Allergan by 6.2% in the third quarter. ETRADE Capital Management LLC now owns 5,641 shares of the company’s stock valued at $1,156,000 after purchasing an additional 327 shares during the last quarter. Motco grew its stake in Allergan by 1.9% in the third quarter. Motco now owns 18,349 shares of the company’s stock valued at $3,760,000 after purchasing an additional 347 shares during the last quarter. Finally, One Capital Management LLC grew its stake in Allergan by 2.6% in the fourth quarter. One Capital Management LLC now owns 13,794 shares of the company’s stock valued at $2,256,000 after purchasing an additional 355 shares during the last quarter. Hedge funds and other institutional investors own 78.40% of the company’s stock.
In related news, CFO Matthew M. Walsh purchased 1,000 shares of the firm’s stock in a transaction on Thursday, March 8th. The stock was bought at an average cost of $153.96 per share, with a total value of $153,960.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider William Meury sold 58,879 shares of the business’s stock in a transaction that occurred on Wednesday, February 14th. The shares were sold at an average price of $160.62, for a total value of $9,457,144.98. The disclosure for this sale can be found here. Insiders acquired 7,200 shares of company stock valued at $1,108,267 over the last three months. 0.36% of the stock is currently owned by corporate insiders.
Allergan plc (NYSE AGN) traded up $2.92 during trading on Wednesday, hitting $166.11. The company had a trading volume of 433,031 shares, compared to its average volume of 3,389,018. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.16 and a quick ratio of 1.06. Allergan plc has a 12-month low of $142.81 and a 12-month high of $256.80. The firm has a market capitalization of $56,850.00, a P/E ratio of -13.61, a price-to-earnings-growth ratio of 1.12 and a beta of 1.29.
Allergan (NYSE:AGN) last announced its quarterly earnings results on Tuesday, February 6th. The company reported $4.86 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $4.74 by $0.12. Allergan had a positive return on equity of 8.43% and a negative net margin of 26.32%. The company had revenue of $4.33 billion during the quarter, compared to the consensus estimate of $4.28 billion. During the same period in the previous year, the company posted $3.90 earnings per share. Allergan’s revenue for the quarter was up 12.0% on a year-over-year basis. analysts expect that Allergan plc will post 15.58 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Wednesday, March 28th. Shareholders of record on Wednesday, February 28th will be issued a $0.72 dividend. The ex-dividend date of this dividend is Tuesday, February 27th. This is an increase from Allergan’s previous quarterly dividend of $0.70. This represents a $2.88 dividend on an annualized basis and a yield of 1.73%. Allergan’s payout ratio is presently -24.02%.
COPYRIGHT VIOLATION NOTICE: “Crestline Management LP Invests $4.73 Million in Allergan plc (AGN)” was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2018/03/14/crestline-management-lp-invests-4-73-million-in-allergan-plc-agn.html.
Allergan Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.